RA0124

antibody from Oursmab

Targeting: CD52 CDW52, EDDM5, HE5

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0124

Provider

Oursmab

Product name

Alemtuzumab (Biosimilar Reference Antibody) (CD52)

Antibody type

Monoclonal

Description

Alemtuzumab is a humanized IgG1 monoclonal antibody targeting the cell surface glycoprotein CD52. It is approved for the treatment of relapsing-remitting multiple sclerosis and B-cell chronic lymphocytic leukemia. Its therapeutic mechanism involves rapid and profound depletion of circulating lymphocytes (T and B cells) and monocytes through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Following this "immune reset," a distinctive repopulation of the immune system occurs over months to years, which in MS is associated with long-term suppression of disease activity. Treatment requires careful monitoring due to significant risks, including serious infections and secondary autoimmune disorders.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.